Crossmark

Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?

Crossref DOI link: https://doi.org/10.1007/s10620-018-5080-x

Published Online: 2018-04-20

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ilan, Yaron http://orcid.org/0000-0003-0802-1220
License Information

Text and Data Mining valid from 2018-04-20
More Information

Article History

Received: 13 December 2017

Accepted: 16 April 2018

First Online: 20 April 2018

Compliance with ethical standards

:

: Y Ilan is a consultant for Immuron, Teva, Enzo Biochem, Protalix, Therapix, Nasvax, Tiziana, Immune Pharmaceuticals, JTI, and Natural Shield.

Document is current

Any future updates will be listed below